Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 16/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5378588 | 0.93 | TRPM8 (0.38) | TRPM8ALDH1A1HCRTR2KDM4EPKM | |
| SCHEMBL5371938 | 0.89 | TRPM8 (0.39) | TRPM8HCRTR2 | |
| SCHEMBL5368704 | 0.87 | TRPM8 (0.41) | TRPM8ALDH1A1HCRTR2KDM4EPKM | |
| SCHEMBL5382107 | 0.83 | SMN1; SMN2 (0.35) | TRPM8ALDH1A1HCRTR2KDM4EPKM | |
| SCHEMBL5376744 | 0.82 | ALDH1A1 (0.38) | TRPM8ALDH1A1HCRTR2KDM4EPKM | |
| SCHEMBL5368411 | 0.76 | RXRA (0.39) | TRPM8ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5367888 | 0.73 | GAA (0.37) | ALDH1A1KDM4EPKMNPC1RAB9A | |
| SCHEMBL5391241 | 0.73 | ALDH1A1 (0.35) | TRPM8ALDH1A1HCRTR2NPC1RAB9A | |
| SCHEMBL5422149 | 0.72 | SERPINE1 (0.53) | TRPM8HCRTR2 | |
| SCHEMBL5377050 | 0.70 | SMN1; SMN2 (0.41) | ALDH1A1KDM4EPKMNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725524-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | Pfizer Products Incorporated (US) | 2006-11-29 | — | — | EP | claimed |
| US-20060258723-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PFIZER INC | 2006-11-16 | — | — | US | claimed |
| US-20050228015-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-10-13 | — | — | US | claimed |
| WO-2005092845-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2005-10-06 | — | — | WO | claimed |
| US-7262318-B2 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| EP-1725524-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | Pfizer Products Incorporated (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20060258723-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PFIZER INC | 2006-11-16 | — | — | US | disclosed |
| US-20050228015-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-10-13 | — | — | US | disclosed |
| WO-2005092845-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228015-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | TRPM8 4317/4885ALDH1A1 2956/4885HCRTR2 3933/4885 |
| US-20060258723-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PPARG, PPARA, PPARD | TRPM8 4175/4885ALDH1A1 2752/4885HCRTR2 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.